Abivax : Financial visibility out to Q4 2025 confirmed
>No surprises in the first-half results - The company reported an operating loss of € 80.0m for H1 2024 vs a loss of € 37.3m last year. The difference is due to operating costs which increased by € 47m to € 86.8m including growth of 1/ € 32.1m for R&D (€ 64.7m in H1 2024 vs € 32.6m in H1 2023) due mainly to progress on the clinical phase III programme for obefazimod in UC, 2/ € 4.2m for S&M expenses (€ 4.2m vs € 0.2m ) relating to the preparation of the launch of obef...ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.